Cyclophosphamide crosses the placenta and may cause teratogenesis. In the initial pregnancy, the drug should be used only when the expected benefits clearly outweigh the potential risks. Use in patients of child-bearing potential should be cautioned.
Cyclophosphamide is excreted in breast milk. Breast feeding should be discontinued prior to the drug therapy.